Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Bids €308m To Buy Kiadis

Premium of 272%

Executive Summary

Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."

You may also be interested in...



Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

Deal Snapshot: CRISPR-Cas9 co-inventor Jennifer Doudna-founded gene-editing firm inks its second large collaboration, teaming with Sanofi on off-the-shelf natural killer cell therapies for cancer.

Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.

Sanofi Adds mRNA Specialist Tidal To Acquisition Spree

Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel